Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Simon Williamson Clinic
• Collaborator: Helsinn Healthcare SA
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• CHEMOTHERAPY NAIIVE

• patient receiving moderately or highly emetogenic chemotherapy

• lung cancer

• breast cancer

Exclusion Criteria:

• PRIOR CHEMOTHERAPY for any cancer

• nausea or vomiting 24 hours prior to study entry